CVS partially dropping Humira in favor of cheaper biosimilars
CVS Caremark, a CVS Health company, announced this week the continuation of its efforts to expand adoption of biosimilars. Effective April 1, 2024, Humira will be removed from our major national commercial template formularies and Humira biosimilars will be covered.